Triple antiviral therapy with PEG-interferon-alfa/ribavirin+amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to standard interferon/ribavirin combination. Patients with hepatitis C virus infection, were eligible if they had failed to respond to a single previous 24 week cycle of interferon/ribavirin combination therapy. Non-response was defined as persistent HCV RNA in the serum during the last month of treatment. This study tested the efficacy and safety of pegylated interferon alfa-2b with ribavirin and amantadine or a placebo for 48 weeks.

Condition	Intervention	Phase
Hepatitis C, Chronic	Drug: peg-interferon alfa-2b  Drug: ribavirin  Drug: amantadine	Phase III

Further Study Details: 

Primary Outcomes: Sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation at week72
Secondary Outcomes: Biochemical response at week 72 defined as ALT normalization; Histological benefit; Tolerance; Virological and biochemical responses during therapy at weeks 12, 24 and 48
Expected Total Enrollment:  405

Triple antiviral therapy with PEG-interferon-alfa/ribavirin+amantadine was suggested to increase sustained virological response (SVR) rates in HCV non-responders to standard interferon/ribavirin combination. The Aim of this study is to determine if the addition of amantadine to PEG-IFN/ribavirin enhances SVR. These study is a double blind, comparative, prospective multicenter, randomized study. Patients are recruited from 23 hepatology centers in France. The protocol was approved by the French ethical committee and all patients provided written informed consent. Eligible subjects are randomly assigned the two treatment groups in equal proportions. The randomization process is generated by the Department of Biostatistics, Hospices Civils de Lyon, Lyon, France. Main Inclusion criteria are : elevated ALT, detectable HCV-RNA, Metavir score over or equal toA1F1 and below or equal to F3. Patients received PEG-IFN 1.5µg/kg/week, ribavirin 800-1200mg/day and amantadine 200mg/day or placebo during 48 weeks. The primary endpoint is a sustained virological response, defined as an undetectable HCV-RNA 24 weeks after treatment discontinuation (week 72). Secondary endpoints is the biochemical response at week 72 defined as ALT normalization, histological benefit, tolerance, as well as virological and biochemical responses during therapy at weeks 12, 24 and 48.

Ages Eligible for Study:  18 Years   -   65 Years

Criteria

Inclusion Criteria: - Positive anti-HCV antibody test - Patients who did not respond to treatment with standard interferon + ribavirin (HCV-RNA + by - PCR in the last month of treatment) - Compensated liver disease - Neutrophil count over or equal to1000/mm3 - Platelet count over or equal to 100 giga/L - Haemoglobin over or equal to 10g/dL - Patients had to have undergone a post-treatment liver biopsy within a year, showing a METAVIR histological score over or equal to A1F1, without cirrhosis (fibrosis score below F4) - ALT over N and HCV-RNA + at screening Exclusion Criteria: - Co-infection with hepatitis B or human immunodeficiency virus - Any other cause of liver disease - Active drug abuse, active alcohol consumption above 40g/day - Organ grafts - Presence of hepatocellular carcinoma - Cardiovascular, metabolic, renal, haematological, neurological or psychiatric disease - Patients with previous amantadine use - Systemic immunosuppressive or antiviral treatment during the last 24 weeks and those with a history of interferon and/or ribavirin intolerance were also excluded.

France
      Service d’Hépato-Gastroentérologie Hopital Hotel Dieu, Lyon Cedex,  69288,  France

Study chairs or principal investigators

Christian Trepo, MD,  Principal Investigator,  Hépato-Gastroentérologie Hopital Hôtel-Dieu LYON   
P. ADELEINE, MD,  Study Chair,  Laboratoire d’Informatique Médicale Lyon   

Study ID Numbers:  ANRSHC03 BITRI
Record last reviewed:  July 2005
Last Updated:  July 25, 2005
Record first received:  July 21, 2005
ClinicalTrials.gov Identifier:  NCT00122629
Health Authority: France: Afssaps - French Health Products Safety Agency
ClinicalTrials.gov processed this record on 2005-07-26